Yoo Joo Jeong, Hyun-Ju Lee, Jun-Su Kim, Seung-Jae Kim, Unhui Jo, Jin Yeop Park, Su Jin Jun, Won Seok Lee, Mingoo Song, Donggii Kim, Gyoujin Cho, Jeong-Heon Song, Hyang-Sook Hoe
{"title":"阿尔茨海默病和帕金森病的数字治疗：当前趋势和未来前景。","authors":"Yoo Joo Jeong, Hyun-Ju Lee, Jun-Su Kim, Seung-Jae Kim, Unhui Jo, Jin Yeop Park, Su Jin Jun, Won Seok Lee, Mingoo Song, Donggii Kim, Gyoujin Cho, Jeong-Heon Song, Hyang-Sook Hoe","doi":"10.1002/med.70005","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD) and Parkinson's disease (PD), which are characterized by the accumulation of misfolded protein aggregates and cognitive/motor dysfunction, are the most prevalent neurodegenerative diseases (NDDs). Despite strategic investigations aimed at augmenting the pharmaceutical pipeline, available drugs for AD and PD merely slow disease progression without curing or treating the underlying pathology. Recent technological advances have given rise to digital therapeutics (DTx): software systems that aim to prevent, cure, and manage specific diseases, including NDDs. For AD and PD, the majority of DTx focus on enhancing cognitive/executive function and motor-related functions, respectively. In this review, we describe the status of therapeutic development for AD and PD, as well as the characteristics and status of DTx targeting these NDDs. In addition, we address the limitations and challenges of DTx and their implications for the treatment of AD and PD. Ultimately, this review provides insights into the potential of DTx as a therapeutic modality and future directions for the development of DTx targeting AD and PD.</p>","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":" ","pages":""},"PeriodicalIF":11.6000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Digital Therapeutics for Alzheimer's and Parkinson's Diseases: Current Trends and Future Perspectives.\",\"authors\":\"Yoo Joo Jeong, Hyun-Ju Lee, Jun-Su Kim, Seung-Jae Kim, Unhui Jo, Jin Yeop Park, Su Jin Jun, Won Seok Lee, Mingoo Song, Donggii Kim, Gyoujin Cho, Jeong-Heon Song, Hyang-Sook Hoe\",\"doi\":\"10.1002/med.70005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Alzheimer's disease (AD) and Parkinson's disease (PD), which are characterized by the accumulation of misfolded protein aggregates and cognitive/motor dysfunction, are the most prevalent neurodegenerative diseases (NDDs). Despite strategic investigations aimed at augmenting the pharmaceutical pipeline, available drugs for AD and PD merely slow disease progression without curing or treating the underlying pathology. Recent technological advances have given rise to digital therapeutics (DTx): software systems that aim to prevent, cure, and manage specific diseases, including NDDs. For AD and PD, the majority of DTx focus on enhancing cognitive/executive function and motor-related functions, respectively. In this review, we describe the status of therapeutic development for AD and PD, as well as the characteristics and status of DTx targeting these NDDs. In addition, we address the limitations and challenges of DTx and their implications for the treatment of AD and PD. Ultimately, this review provides insights into the potential of DTx as a therapeutic modality and future directions for the development of DTx targeting AD and PD.</p>\",\"PeriodicalId\":207,\"journal\":{\"name\":\"Medicinal Research Reviews\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":11.6000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicinal Research Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/med.70005\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/med.70005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Digital Therapeutics for Alzheimer's and Parkinson's Diseases: Current Trends and Future Perspectives.
Alzheimer's disease (AD) and Parkinson's disease (PD), which are characterized by the accumulation of misfolded protein aggregates and cognitive/motor dysfunction, are the most prevalent neurodegenerative diseases (NDDs). Despite strategic investigations aimed at augmenting the pharmaceutical pipeline, available drugs for AD and PD merely slow disease progression without curing or treating the underlying pathology. Recent technological advances have given rise to digital therapeutics (DTx): software systems that aim to prevent, cure, and manage specific diseases, including NDDs. For AD and PD, the majority of DTx focus on enhancing cognitive/executive function and motor-related functions, respectively. In this review, we describe the status of therapeutic development for AD and PD, as well as the characteristics and status of DTx targeting these NDDs. In addition, we address the limitations and challenges of DTx and their implications for the treatment of AD and PD. Ultimately, this review provides insights into the potential of DTx as a therapeutic modality and future directions for the development of DTx targeting AD and PD.
期刊介绍：
Medicinal Research Reviews is dedicated to publishing timely and critical reviews, as well as opinion-based articles, covering a broad spectrum of topics related to medicinal research. These contributions are authored by individuals who have made significant advancements in the field.
Encompassing a wide range of subjects, suitable topics include, but are not limited to, the underlying pathophysiology of crucial diseases and disease vectors, therapeutic approaches for diverse medical conditions, properties of molecular targets for therapeutic agents, innovative methodologies facilitating therapy discovery, genomics and proteomics, structure-activity correlations of drug series, development of new imaging and diagnostic tools, drug metabolism, drug delivery, and comprehensive examinations of the chemical, pharmacological, pharmacokinetic, pharmacodynamic, and clinical characteristics of significant drugs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
